Citizens lifts target to USD 65 for Exelixis stock

Published on 10/20/2026 at 20:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Exelixis reported USD 628.69 million revenue in Q2 2026, up 10.60 percent. Exelixis stock costs EUR 56.84 on October 20, 2026.

Analyst target and earnings

Citizens raised its Exelixis target from USD 55.00 to USD 65.00 on October 19, 2026.
Second-quarter 2026 revenue reached USD 628.69 million, up 10.60 percent year over year.
Exelixis stock costs EUR 56.84 at Lang & Schwarz on October 20, 2026 at 8:44 p.m. CEST.
Exelixis is scheduled to release third-quarter 2026 earnings on October 29, 2026.

EXEL, US30161Q1040, Illustration mit AI erstellt.

Citizens raised its Exelixis price target from USD 55.00 to USD 65.00 on October 19, 2026, while maintaining a Market Outperform rating, according to Investing.com. The stock was trading at EUR 56.84 at Lang & Schwarz on October 20, 2026 at 8:44 p.m. CEST.

Citizens sees a USD 65 target

The revised target represents an 18.18 percent increase from Citizens' previous USD 55.00 level. The firm cited presentations involving cabozantinib at ESMO 2026, including data related to Exelixis' oncology franchise, Investing.com reported.

Revenue rose 10.60 percent

Exelixis generated USD 628.69 million of revenue in the second quarter of 2026, a 10.60 percent year-over-year increase. The figure was below the USD 636.40 million consensus cited by MarketBeat, while quarterly earnings per share reached USD 0.91 against a USD 0.85 consensus. Exelixis had issued 2026 revenue guidance of USD 2.50 billion to USD 2.55 billion on August 5, 2026, according to its investor-relations site.

Price position and next date

Exelixis' primary listing is Nasdaq under ticker EXEL. Its market capitalization was USD 16.1 billion and its trailing P/E ratio was 20.03 as of October 20, 2026. The next scheduled reporting date is October 29, 2026, when Exelixis is expected to release third-quarter 2026 results, according to MarketScreener.

What the target means for valuation

Citizens' USD 65.00 target stands above Exelixis' current USD 63.93 Nasdaq price, a 1.67 percent premium based on the October 20, 2026 quote. By contrast, MarketBeat reported an average 12-month target of USD 50.79 from 20 covering firms on October 17, 2026, placing the broader consensus below the latest Citizens view.

Exelixis stock after hours

Exelixis was trading at EUR 56.84 at Lang & Schwarz on October 20, 2026 at 8:44 p.m. CEST. The euro quotation gives German investors a live after-hours indication, while the Nasdaq listing remains the company's primary market.

The further course of trading is shown by the continuously updated real-time quote of Exelixis stock.